In breast cancer, higher expression of IL-6 and DCLK1 predicts shorter recurrence-free survival in TNBC but not in luminal A, luminal B and HER2 subtypes, which suggests the critical roles of DCLK1 and IL-6 in tumor recurrence of TNBC. Here, ERBB2 is linked to breast carcinoma.